TRANSIL HSA Binding Kit

Sovicell Verified independent store

→

Determination of Drug-Albumin Binding Constants for Prediction of Plasma Protein Binding The TRANSIL HSA Binding Kit determines the binding affinity (KD) of test compounds to human serum albumin under well-defined experimental conditions. These affinity constants enable prediction of plasma protein binding and free drug fraction during drug discovery and development. Why Albumin Binding Matters Most drug molecules are reversibly bound to proteins in plasma. Only the unbound fraction (fu) can cross biological membranes, interact with pharmacological targets, or undergo metabolic elimination. Plasma protein binding therefore strongly influences drug exposure, pharmacokinetics, and pharmacological activity. Human serum albumin (HSA) is the most abundant plasma protein and represents the principal binding partner for many drugs, particularly lipophilic compounds. Because albumin binding can substantially reduce the circulating free drug concentration, accurate characterization of drug–albumin interactions is an important component of ADME profiling and lead optimization. Albumin binding influences many key parameters in ADME and DMPK, including: prediction of the unbound drug fraction in plasma interpretation of potency in serum-containing assays estimation of clearance, half-life, and volume of distribution assessment of potential drug–drug interactions modeling of drug exposure under varying physiological conditions The measured KD can be used to estimate plasma protein binding across different albumin concentrations, reflecting physiological variability or disease-associated changes in protein levels. Limitations of Conventional Plasma Protein Binding Assays Conventional approaches for measuring plasma protein binding, such as equilibrium dialysis, ultrafiltration, and ultracentrifugation, directly determine the free fraction of a compound in plasma. While widely used, these methods can be time-consuming and experimentally demanding, often requiring long equilibration times and careful control of experimental conditions. In addition, adsorption to membranes or plastic surfaces, compound instability, and analytical sensitivity limitations can complicate the accurate measurement of highly bound compounds. These challenges make it difficult to apply traditional methods efficiently in high-throughput drug discovery workflows. The TRANSIL Approach Unlike plasma-based methods, the TRANSIL approach determines intrinsic drug–albumin binding affinity under controlled conditions, allowing plasma protein binding to be predicted across different physiological albumin concentrations. The TRANSIL HSA Binding Kit determines albumin binding affinity by measuring the dissociation constant (KD) of the interaction between a test compound and human serum albumin. In the assay, compounds are incubated with increasing concentrations of albumin immobilized on high-surface-area beads under well-defined experimental conditions. The resulting binding data are used to calculate the affinity constant of the drug-albumin interaction, which provides a mechanistic description of protein binding. Because the KD describes the intrinsic drug–albumin interaction and is independent of protein concentration, it can be used to predict plasma protein binding and free drug fraction under physiological conditions and across different albumin concentrations. How the Assay Works The assay determines albumin binding affinity through the following experimental workflow: Test compound is added at constant concentration to 8 wells The compound is incubated with increasing concentrations of bead-immobilized albumin Beads are separated, leaving only free drug in solution Free drug concentration is quantified (e.g., by LC–MS/MS) Binding affinity (KD) is calculated from the slope of binding versus protein concentration Features and Benefits Membrane-free binding measurement Immobilization of albumin on beads eliminates the need for dialysis membranes, a accelerating equilibration between compound and protein while avoiding artifacts caused by membrane adsorption or slow diffusion through dialysis membranes. Rapid equilibrium measurements Immobilized albumin on high-surface-area beads enables equilibrium binding measurements within 12 minutes or less rather than the hours required for dialysis-based methods. Mechanistic characterization of albumin binding Determines the drug–albumin dissociation constant (KD), providing a mechanistic description of the interaction and enabling prediction of plasma protein binding across different physiological protein concentrations. Robust performance for challenging compounds Affinity is derived from the relationship between binding and protein concentration, making the method largely insensitive to compound loss caused by nonspecific adsorption or limited recovery. Stable and controlled pH conditions The assay is performed in a well-defined buffered environment, preventing errors in free fraction (fu) estimation caused by pH shifts that can occur in dialysis experiments. Well-defined experimental conditions Binding is measured against purified albumin at controlled concentrations, reducing variability associated with plasma composition and improving reproducibility. High-throughput assay format The 96-well format allows analysis of up to 12 compounds per plate, supporting efficient profiling during lead optimization. Compatibility with standard analytical methods Free compound concentration can be quantified using LC–MS/MS, HPLC, or other commonly used analytical techniques, allowing integration into existing workflows. Integrated internal quality control The TRANSIL Quality Index (TQI) evaluates data reliability using multiple statistical and experimental metrics, providing an objective assessment of assay performance within each experiment. Validation Against Literature and Equilibrium Dialysis The predictive performance of the TRANSIL HSA Binding assay was evaluated using a validation set of 26 structurally diverse drugs with plasma protein binding values reported in the literature or determined by equilibrium dialysis. The compounds covered a broad range of binding affinities, corresponding to fraction unbound values between 1% and 50%. Plasma protein binding estimates calculated from the measured albumin binding constants showed strong agreement with reference data (R² = 0.93), demonstrating that the mechanistic determination of albumin binding affinity provides a reliable basis for predicting plasma protein binding. For most compounds, measurements obtained with the TRANSIL HSA Binding Kit alone provide an accurate approximation of plasma protein binding. Only compounds with relatively weak albumin binding but strong interaction with α1-acid glycoprotein, such as propranolol, show a substantial shift in the predicted unbound fraction when AGP binding is included. These results demonstrate that mechanistic determination of albumin binding affinity provides a reliable basis for predicting plasma protein binding during early drug discovery. Figure 1: Comparison of plasma protein binding measurements obtained with the TRANSIL assay kits and dialysis as well as comparison with literature data (Goodman and Gilman 1996: The Pharmacological Basis of Therapeutics). Why can results from the TRANSIL HSA Binding kit differ from literature values? Most literature values were obtained by dialysis experiments. Usually, dialysis experiments use pooled plasma that is not controlled for its exact protein composition. However, even minor changes in both HSA and AGP concentration can have major effects on the fraction unbound of some drug candidates. Also, most literature values date back to times when there was no awareness of the influence of pH shifts during the dialysis experiment on the results. And only recently has it been recognized that plasticizers in plasma collection bags can have an equally dramatic effect on plasma protein folding and thus binding of drugs. Thus, differences between results from TRANSIL and dialysis experiments are to be expected due to artefacts that can arise and uncontrolled variables in dialysis. What are dissociation constants of marketed drugs? The table below lists dissociation constants for some marketed drugs. Compound KD(HSA) in μM KD(AGP) in μM Propranolol 430.0 5.2 Imatinib 51.8 1.3 Vincristine 123.0 3.9 Paclitaxel 62.0 58.6 Docetaxel 15.0 3.3 Verapamil 357.0 6.1 Sulfasalazine 0.6 27.0 Ketoprofen 1.7 290.0 Warfarin 6.4 8.8 Chlorpromazine 38.0 0.8 Progesterone 8.5 10.0 Can I use the TRANSIL HSA Binding Kit for compounds with plasma instability? When a compound is unstable in plasma equilibrium dialysis fails to report adequate results. However, the TRANSIL HSA binding assay performs well under these conditions, because incubation time is 15 minutes or less and there are no enzymes present in the assay system that would degrade the compound. Can I use the TRANSIL HSA Binding Kit for compounds that are unstable? When a compound is unstable and degrades within hours during equilibrium dialysis results will not be useful. However, the TRANSIL HSA binding assay performs well under these conditions, because incubation time can be reduced to only 2 minutes. Will it be necessary to run the TRANSIL HSA Binding assay in a controlled CO2 atmosphere like it is required for dialysis? No, there are two reason why this is not needed. Remember, the CO2 atmosphere is needed for dialysis because there is only a low buffer capacity in the system which makes it susceptible to pH changes by diffusion of CO2. That pH change then results in biased plasma protein binding estimates. This doesn’t happen in the TRANSIL HSA Binding Kit as comes with a strong phosphate buffer, thus diffusion of CO2 will not alter the pH. Also, the kit is only incubated for 12 minutes instead of several hours which minimizes the potential impact of CO2-concentration changes. Why is plasma protein binding important? The extent of binding to plasma influences the way in which a drug distributes into tissues in the body. If a compound is highly bound, then it is retained in the plasma, which results in a low volume of distribution. This may impact on the therapeutic effects of the compound by limiting the amount of free compound which is available to act at the target molecule. Extensive plasma protein binding also limits the amount of free compound available to be metabolized which can, in turn, reduce the clearance of the compound. Why is it useful measuring the dissociation constant KD instead of the fraction unbound? Healthy humans have a plasma composition that breaks down into 60% albumin and 40% globulins. The latter break down into 4% α1 globulins, of which α1 acid glycoprotein is only a small part, 8% α2 globulins (e.g. haptoglobulin, macrogobulin etc), 12% β globulins, and 16% γ globulins (i.e. our antibodies). However, these are textbook number referring to healthy humans. The plasma composition changes with age, race, sex, and disease condition and the unbound fraction of a drug can change accordingly (Figure 3). In fact, it has been shown that, for example, a 2-fold change in the AGP (AAG) concentration can lead to a 3-fold reduction in survival time of NSCLC patients treated with docetaxel. Thus, measuring the dissociation constant KD of your discovery compound to the major plasma proteins HSA and AGP can be critical in many indication areas. Figure 2: Illustration of the reduction of the unbound fraction in response to an increasing AGP (AAG) content of human plasma. Which compounds can I use as positive and negative controls in the TRANSIL HSA Binding Kit? For instance, as a positive control you can use warfarin (KD=6.4 µM), and as a negative control compound you can use propranolol (KD=430 µM). What are the main quality control measures applied in TRANSIL assays? The TRANSIL Quality Index (TQI) is based on independent measures derived from the data analysis. Overall fit of the data to the standard protein binding model Recovery: does the model derived compound concentration equal the true concentration? Data consistency: does membrane binding increase proportionally with the increasing TRANSIL bead content in each well? Data consistency: are the estimated reference concentrations in alignment with the compound concentration used? Missing data and outliers. How long does it take to run the assay? One assay plate can be used for 12 compounds. Thus, you’ll need to pipette 15 µl of test item to each of 8 wells and repeat this for all 12 compounds. This takes less than 10 minutes even with manual pipetting. After compound addition, the plate is ready for incubation. You can do this with an electronic 8 or 12 channel pipette by aspirating and dispensing a volume of 120 µl for 15 times. That takes just over a minute for each column or row. In total, that makes 8 to 15 minutes depending on your pipette. When using a pipetting robot with a 96 well head this time decreases to 2 minutes. After incubation, the plate needs to be spun in a plate centrifuge for 10 minutes. The supernatants are then ready for quantification by LC/MS/MS, UV, fluorescence or any other method of your choice. Thus, the total time the start and end of the experiment varies between 7 and 25 minutes depending upon your equipment. How many compounds can be analyzed with one plate? One assay plate can be used for 12 compounds. A special feature of the 96 well plates used for these kits is that each of the 12 columns can be separated from the plate. Thus, it is possible to use the plate for one compound at a time. Are TRANSIL assay kits supplied in low-binding plates? The TRANSIL assay kits utilize Micronic 96 well plates with ultra-low-binding tubes. Standard polypropylene tubes have 41x higher non-specific binding and low-binding tubes from other vendors have 2.6x higher non-specific binding. Show more